Smarter strategy
for high-stakes
oncology decisions.

The decisions made during clinical development are among the most consequential in biopharma. We provide senior strategic counsel on programme design, trial strategy, and the critical go/no-go choices that determine whether an asset reaches its full potential — and on what terms.

Winning in oncology requires the right evidence, built from the start. We help clients design integrated evidence strategies that generate the data needed to convince every audience — clinical, regulatory, and commercial — at every stage of the asset journey.

The environment around your asset is shaped by people — clinicians in academia and community, payers, patient advocates, and partners. We help clients define strategies to engage the stakeholders who matter most, build the relationships and advocacy that underpin long-term asset and patient outcomes.

Good strategy starts with clear insight. We combine deep sector expertise with advanced AI and analytical tools to turn data, research, and competitive intelligence into the sharp, actionable understanding that leadership teams need to make confident decisions.

The biggest decisions in oncology — a Phase II/III go-decision, a launch strategy, an asset repositioning — demand more than insight. They demand a plan. We help leadership teams translate strategic thinking into concrete, executable programmes, aligning stakeholders and mobilising the right capabilities to move with confidence in a complex, fast-moving market.

In high-stakes situations, decisions rarely wait. Whether evaluating an in-licensing opportunity, assessing a competitor asset, or scanning a target landscape under time pressure — we deliver rapid, rigorous analysis when signal is scarce and the clock is running. Clear-eyed diligence, built for the pace and complexity of oncology deal-making.